AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06127498 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: A8G6 SARS-CoV-2 Neutralization Antibody nasal excipient
Description: Subjects in each cohort were randomly assigned 5:1 to two parallel administration groups, one of which served as a control. Each cohort was given either the experimental drug or placebo by nasal spray at different doses and intervals, and blood was collected on an empty stomach before the first dose. Right nostril and nasal swabs were collected for immunotoxicity, immunogenicity (immunogenicity collection and detection in cohorts 3 and 4 only), and drug concentration detection. Subjects in the first three cohort were required to return to the study Center 3±1 days after the last dose for blood samples, bilateral nostril and nasal swabs for drug concentration, immunotoxicity, physical examination, vital signs, and safety laboratory indicators (blood routine, blood biochemical, and urine routine). Subjects in cohort 4 returned to the study center 7±2 days after the last dose.
Study NCT05332015 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hypotonic (distilled) water
Description: orally given daily two liters of distilled water
Study NCT05332015 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Normal water
Description: orally given daily two liters of normal water
Study NCT05641909 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: Remifentanil
Study NCT05641909 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Dosage forms and strengths: 50 mcg/mL Fentanyl base/10 mL ampules. Manufacturer: Yichang Humanwell Pharmaceutical Co.,Ltd
Study NCT05627427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Surufatinib
Description: 250mg, p.o., qd, q3w, until disease progression or other treatment termination criteria
Study NCT05627427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: 200mg, IV, D1, q3w, until disease progression or other treatment termination criteria
Study NCT06234670 — intervention group
Intervention type: OTHER
Intervention: No intervertion
Description: This study is a retrospective observational study without intervention.
Study NCT04855786 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thoracic duct drainage
Description: drain placement into the thoracic duct
Study NCT05702424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IGM-7354
Description: IGM-7354 is a PD-L1-targeted cytokine that is designed to regulate T and natural killer cell activation, proliferation and promote their anti-tumor effects
Study NCT05554822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin 100mg
Description: Single antiplatelet therapy with aspirin 100 mg OD for 6 months after the procedure
Study NCT05554822 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin 100 mg OD plus clopidogrel 75 mg OD
Description: Double antiplatelet therapy with Aspirin 100 mg OD plus clopidogrel 75 mg OD for 3 months, followed by 3 months of single antiplatelet therapy with aspirin 100 mg OD.
Study NCT04929626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Sulfate 500 mg/ml+ ventolin
Description: 3 doses of magnesium sulphate i.e; 250mg(0.5ml), 500mg(1ml), 750mg(1.5ml) will be used in nebulized form
Study NCT04929626 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ventolin
Description: it will be given to control group in nebulized form after every 20 min in 1st hour
Study NCT04929223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inavolisib
Description: Inavolisib will be administered orally as per schedule specified in the respective arms.
Study NCT04929223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab IV will be administered as per schedule specified in the respective arm.
Study NCT04929223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab IV will be administered as per schedule specified in the respective arm.
Study NCT04929223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab IV infusion will be administered as per schedule specified in the respective arm.
Study NCT04929223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiragolumab
Description: Tiragolumab IV infusion will be administered as per schedule specified in the respective arm.
Study NCT04929223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SY-5609
Description: SY-5609 will be administered by mouth as per schedule specified in the respective arm.
Study NCT04929223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Divarasib
Description: Divarasib will be administered orally as per schedule specified in the respective arms.
Study NCT04929223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX
Description: FOLFOX (5-fluorouracil, leucovorin, oxaliplatin) IV will be administered as per schedule specified in the respective arm.
Study NCT04929223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI
Description: FOLFIRI (leucovorin, 5-fluorouracil, irinotecan) IV will be administered as per schedule specified in the respective arm.
Study NCT06374459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zumsemetinib
Description: Patients should take zunsemetinib at approximately the same times every day, with or without food with 8 oz of water.
Study NCT06374459 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Patients should take capecitabine at approximately the same times every day, within 30 minutes after a meal.
Study NCT06374459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Patients should take capecitabine at approximately the same times every day, within 30 minutes after a meal.
Study NCT06374459 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zoledronic acid
Description: Standard of care. Will receive zoledronic acid or denosumab.
Study NCT06374459 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Denosumab
Description: Standard of care. Will receive zoledronic acid or denosumab.
Study NCT06185790 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LCHF diet
Description: Low-carb high-fat (LCHF) diet
Study NCT06426056 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: Image guidance volume modulated arc therapy included 50.4 Gy in 28 fractions to the pelvis and 59.4 Gy simultaneous boost in 28 fractions to involved pelvic and para-aortic lymph nodes, and subsequent high-dose-rate intracavitary brachytherapy at a total dose of 30.0-36.0 Gy in 5-6 fractions, twice a week.
Study NCT06426056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: Concurrent chemotherapy regimen included weekly cisplatin (40 mg/m\^2) and weekly nab-paclitaxel at escalating doses (33 mg/m\^2 per week).
Study NCT06426056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Concurrent chemotherapy regimen included weekly cisplatin (40 mg/m\^2) and weekly nab-paclitaxel at escalating doses (33 mg/m\^2 per week).
Study NCT02912897 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cellular therapy with EBV specific autologous CTL infusion
Description: CTL infusions at D0, M3 and M6
Study NCT04992052 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bone wax
Description: The surgeons will apply the bone wax to the exposed cancellous bone after the implant has been cemented in place in patients randomized to the treatment arm.
Study NCT04114448 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic exercise
Description: Patients will perform an exercise protocol specifically designed for patients with hemophilia that will include exercises focused on improving range of movement, strength, flexibility, balance and coordination as well as diaphragmatic breathing at the start and at the beginning of each session.
Study NCT04114448 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual physical therapy care
Description: Patients will undergo usual physical therapy treatment for hemophiliacs, based on affected self and gentle joint mobilization and stretching of muscles involved in the affected joints.
Study NCT05586009 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin with hydration magnesium
Description: Optimal doses of magnesium in prevention cisplatin induced nephrotoxicity
Study NCT04776551 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Percutaneous fixation of acute Scaphoid fractures
Description: Percutaneous Trans-trapezial fixation of acute Scaphoid fractures by Herbert screw
Study NCT05739045 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nivolumab combined with SOX
Description: nivolumab + SOX (3 cycles) before surgery → radical surgery (D2) → nivolumab + SOX (3 cycles) after surgery → nivolumab monotherapy maintenance (11 cycles);
Study NCT05998642 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: 3.5mg/m2 IV
Study NCT05998642 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab (where available)
Description: 375mg/m2 / 1400mg IV or SC
Study NCT05998642 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Dose and schedule assigned at enrollment
Study NCT04815902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fisetin
Description: Oral Fisetin 20 mg/kg taken for 10 days total.
Study NCT04815902 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fisetin
Description: Oral Fisetin 20 mg/kg taken for 10 days total.
Study NCT04815902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan
Description: 12.5 mg oral Losartan taken for 30 days total.
Study NCT04815902 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Losartan
Description: 12.5 mg oral Losartan taken for 30 days total.
Study NCT04815902 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo - Losartan
Description: Losartan appearance-matched microcrystalline cellulose placebo. 12.5 taken for 30 days total.
Study NCT04815902 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - Losartan
Description: Losartan appearance-matched microcrystalline cellulose placebo. 12.5 taken for 30 days total.
Study NCT04815902 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Fisetin
Description: Fisetin appearance-matched microcrystalline cellulose placebo. 20 mg/kg taken for 10 days total.
Study NCT04815902 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Fisetin
Description: Fisetin appearance-matched microcrystalline cellulose placebo. 20 mg/kg taken for 10 days total.
Study NCT05116930 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neostigmine
Description: IV infusion 20 μg/kg over 10 minutes repeated every 8 hours for a maximum of 3 doses
Study NCT05116930 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate
Description: IV infusion 4 μg/kg over 10 minutes repeated every 8 hours for a maximum of 3 doses
Study NCT04898296 — intervention group
Intervention type: OTHER
Intervention: Questionnaire, Interview
Description: During the stay, a study visit is arranged with the patient after the 6-minute walk test has been performed. This consists of filling out the questionnaire and an interview, which lasts about 45-60 minutes. This is carried out by the investigator on at least 5 subjects. After each interview, a list of influencing factors is kept. If new aspects continue to appear in the 5th interview, the interviews are continued (up to a maximum of the 10th subject). If no new aspects appear in the interviews from number 6 onwards, the interviews are discontinued and no further patients are recruited. The conversations are recorded with an audio recording.
Study NCT04898296 — intervention group
Intervention type: OTHER
Intervention: Focus Group
Description: The focus group is carried out first in order to identify influencing variables that may be relevant for the interview (duration 60-90 minutes).
Study NCT05045118 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Digital Structured Patient Education Material
Description: Participants of home-based Cardiac Rehabilitation Program that are included in this research will be provided with a digital Structured Patient Education Material at the beginning of the program, and will be followed up for 12 weeks duration
Study NCT04946877 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: IQ assessment using Wechsler intelligence scale for children third edition (WISC-III)
Description: IQ assessment using Wechsler intelligence scale for children third edition (WISC-III): is consists of several subtests, each classified into a verbal or performance scale .
Study NCT06263348 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dorzagliatin tablets
Description: During the study, patients should follow the dosing instructions from the investigator, which are made according to the package insert and the patients' conditions.
Study NCT06199297 — intervention group
Intervention type: DRUG
Intervention: Atezolizumab combined with Bevacizumab
Description: Atezolizumab 1200 mg IV d1, Q3W, combined with bevacizumab 15 mg/kg IV d1, Q3W treatment, treatment continued until disease progression, development of intolerable toxic reactions
Study NCT06199297 — intervention group
Intervention type: DRUG
Intervention: Sintilimab combined with Bevacizumab
Description: Sintilimab 200 mg IV d1, Q3W, combined with bevacizumab 15 mg/kg IV d1, Q3W treatment, treatment continued until disease progression, development of intolerable toxic reactions
Study NCT06199297 — intervention group
Intervention type: PROCEDURE
Intervention: Transcatheter arterial chemoembolization and hepatic arterial infusion chemotherapy
Description: The chemoembolization process employed 30 mg/m2 of epirubicin and 2-10 mL of lipiodol. This was followed by FOLFOX-based HAIC, including 85 mg/m2 of oxaliplatin, 400 mg/m2 of leucovorin, and an initial bolus of 400 mg/m2 of 5-FU for 2 h, which was then followed by a sustained infusion of 1200 mg/m2 5-FU for 23 h.
Study NCT04983706 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MRI/Ultrasound Fusion Saturation Biopsy
Description: MRI/Ultrasound fusion saturation biopsy: the core number and location are designed according to the lession condition.
Study NCT06257745 — intervention group
Intervention type: OTHER
Intervention: Compliance with ERACS guideline as described in the current ERACS guidelines from Engelman et al. 2019
Description: Compliance with the interventions as proposed in the ERACS guidelines and described in our previous publication (https://doi.org/10.1016/j.jtcvs.2022.07.010
Study NCT05457101 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AI-based biliopancreatic EUS navigation system
Description: The endoscopists in the experimental group will be assisted by EndoAngel, which can in real-time prompt standard stations and anatomical structures during EUS. The system is an non-invasive AI system .
Study NCT05853484 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bimodal lifestyle program
Description: Participants will be subjected to two training periods of six weeks (or until transplantation) of a semi-supervised home-based bimodal lifestyle program. The bimodal lifestyle program consists of an exercise program combined with nutritional support. The exercise program comprises high intensity interval training and endurance training, combined with peripheral resistance training and breathing exercises
Study NCT05289713 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: appendectomy
Description: Laparoscopic appendectomy is performed within 18 hours after randomization in the surgery group. Patients in the symptomatic treatment group are carefully monitored and the same intervention (laparoscopic appendectomy) is performed in case of treatment failure.
Study NCT05315726 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dynamometer
Description: Measurement of elbow/wrist spasticity
Study NCT05315726 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Muscle vibrations
Description: 1 session of 10 minutes
Study NCT05315726 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Muscle vibrations
Description: 3 times/week for 6 weeks
Study NCT05315726 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo muscle vibration
Description: 3 times/week for 6 weeks
Study NCT05502978 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Blended education of Infant and Young Child Feeding
Description: Blended education is an intervention about IYCF consisting of 3 components: Education via WhatsApp group, counselling face to face, Consultation with nutritionist via WhatsApp call. In the intervention group, participants will get blended education about IYCF provided by trained cadres. Education via WhatsApp group. The implementation of this educational program was carried out for 3 meeting sessions, where previously trained cadres had distributed videos and digital booklets for IYCF material and opened a discussion session at the end of the meeting in WhatsApp group. Face to face Counselling (Home visit). The cadres conduct home visits every month when the participants have given birth until the child is 7 months old. Consultation with nutritionist via WhatsApp call. Consultations were carried out via WhatsApp calls about IYCF practice was for infants aged 1 month, 3 months, 6 and 7 months.
Study NCT06342076 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Patients undergoing subcostal transversus abdominis plane block and posterior transversus abdominis plane block
Description: To prevent postoperative pain, the researchers applied a subcostal transversus abdominis plane block in addition to the posterior transversus abdominis plane block to a group of patients who underwent surgery with a midline incision due to major gynecological cancer.
Study NCT06342076 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Patients undergoing rectus sheat block and posterior transversus abdominis plane block
Description: To prevent postoperative pain, the researchers applied a rectus sheath block in addition to the posterior transversus abdominis plane block to a group of patients who were operated on through a midline incision due to major gynecological cancer.
Study NCT04762056 — intervention group
Intervention type: OTHER
Intervention: Chelsea Critical Care Physical Assessment Tool
Description: Chelsea Critical Care Physical Assessment Tool is a bedside assessment tool firstly reported in 2013 to measure physical morbidity in the critical care population, consisting of 10 items (respiratory function, cough, moving within the bed, supine to sitting on the edge of bed, dynamic sitting, standing balance, sit to stand, transferring from bed to chair, stepping, and grip strength) rated on a 6-point scale from complete dependency (level=0) to independency (level=5). Therefore, the CPAx sum score ranges from 0 (worst condition) to 50 (best functioning/independence)
Study NCT05008822 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motor Imaginary Training Group
Description: After the baseline assessment, the participant will receive Motor Imaginary Program
Study NCT05008822 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Task oriented Training Group
Description: After the baseline assessment, the participant will receive MRP and CIMT training
Study NCT05733715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab infusion
Description: 100 mg/ 4mL on Day 1 of each 3- or 6- week cycle (one 3 wk cycle; up to eight 6 wk cycles)
Study NCT05733715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib tablet
Description: 10mg and 4mg daily for 21 days
Study NCT06346223 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness and psychoeducation
Description: The single-session mindfulness intervention includes a 90-minute group-based session containing different mindfulness practices, psychoeducation and group sharing activities in the single-session mindfulness intervention. A self-practice tool kit will be provided to the participants for home practice 20 minutes daily through an online platform and the participants will be told to develop the practice as a daily habit. All of the teaching contents will be closely related to dementia caregiving and delivered by a mindfulness teacher who has received 40 hours training in dementia caregiving. A weekly mindfulness practice reminder will be sent to the participants through SMS for 8 weeks. The caregivers will also be provided with access to a social media online platform for sharing their practice experience with their classmates online. The interventionist will address their difficulties and challenges via the platform to reinforce skill mastery.
Study NCT06346223 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation
Description: The caregivers in the control group will receive brief education on dementia with the same group size and of the same duration (90-minutes) as the sessions in the intervention arm. The nurse will deliver brief education (15 minutes) on dementia in the session, followed by group sharing and discussion on their daily caregiving experience. The caregivers in the control group will be provided with a toolkit with education materials about the common health problems of older adults and also be given access to a social media platform in which they can communicate and share their caregiving experiences with classmates.